Table 3.

Orthotopic tumor development in mice treated with control or p130cas siRNA with or without docetaxel^*

Cell line and treatment group	Tumor incidence†	Mean No. of tumor nodules (95% CI)	P‡
HeyA8
Control siRNA	80	6.5 (4.15 to 8.86)	referent
p130Cas siRNA	100	3.3 (1.30 to 5.30)	.27
Control siRNA plus docetaxel	100	2.0 (1.49 to 2.31)	<.001
p130Cas siRNA plus docetaxel	100	1.7 (1.02 to 2.38)	<.001
SKOV3ip1
Control siRNA	100	11.5 (6.07 to 26.5)	referent
p130Cas siRNA	100	7.0 (2.80 to 13.20)	.28
Control siRNA plus docetaxel	90	3.0 (2.24 to 5.54)	.01
p130Cas siRNA plus docetaxel	80	2.0 (1.30 to 2.95)	<.001
HeyA8-MDR
Control siRNA	100	5.5 (3.09 to 9.96)	referent
p130Cas siRNA	80	5.0 (1.43 to 6.82)	.24
Control siRNA plus docetaxel	90	3.0 (2.95 to 8.17)	.72
p130Cas siRNA plus docetaxel	90	1.0 (0.06 to 5.05)	.03

^*CI = confidence interval; siRNA = small interfering RNA.

^†Number of mice that developed tumors divided by the number of mice treated.

^‡Mann–Whitney rank sum test (all P values are two-sided).